February 2nd 2023
Closing out their discussion on myeloproliferative neoplasms, key opinion leaders share excitement for future evolutions in the treatment paradigm.
January 26th 2023
Following their overview on novel treatment modalities in myeloproliferative neoplasms, expert panelists consider how best to sequence and manage novel therapies in practice.
A broad and comprehensive review of novel targeted agents under investigation in the setting of myeloproliferative neoplasm management.
January 19th 2023
Key opinion leaders on myeloproliferative neoplasms review the potential of CALR as a therapeutic target following data from the ASH 2022 Annual Meeting.
Expert panelists consider the ongoing role of transplant for patients with myelofibrosis and discuss when it is more appropriate to explore systemic therapy options.
January 12th 2023
Closing out their discussion on the management of myelofibrosis, panelists highlight updated data with fedratinib and ruxolitinib, respectively.
A brief review of the biology of myelofibrosis, the potential for disease modification, and subsequent implications for treatment.
January 5th 2023
Key opinion leaders on myeloproliferative neoplasms review clinical data behind pacritinib therapy in the setting of myelofibrosis.
Switching their focus to myelofibrosis management, expert panelists reflect on clinical data behind momelotinib, a novel JAK2 inhibitor.
June 9th 2022
Taking into account the three JAK inhibitors, ruxolitinib, fedratinib, and pacritinib, experts reflect on the appropriate use of each agent in myelofibrosis.
May 4th 2022
Ruben A. Mesa, MD, discusses the future of JAK inhibitor therapy in myelofibrosis.
April 28th 2022
Expert Stephen Oh, MD, PhD, provides a broad overview of the myeloproliferative neoplasms: polycythemia vera, essential thrombocythemia, and myelofibrosis.
March 1st 2022
Ruben A. Mesa, MD, discusses the accelerated FDA approval of pacritinib (Vonjo) for the treatment of adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.
January 21st 2022
Ruben A. Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses future research efforts with JAK inhibitors in myelofibrosis.
November 19th 2021
Ruben A. Mesa, MD, discusses strategies for navigating the expanding paradigm of JAK inhibitors in myeloproliferative neoplasms.
September 11th 2021
Ruben A. Mesa, MD, discusses the impact of molecular biology on therapeutic development in myelofibrosis.
June 10th 2021
Ruben A. Mesa, MD, discusses the importance of achieving transfusion independence with momelotinib in myelofibrosis.
December 1st 2020
Ruben A. Mesa, MD, discusses the potential role of momelotinib in alleviating myelofibrosis-associated anemia.
October 23rd 2020
Ruben A. Mesa, MD, discusses management strategies for patients with myeloproliferative neoplasms.
October 15th 2020
Ruben A. Mesa, MD, discusses remaining challenges faced in the treatment of patients with myeloproliferative neoplasms.